Search

Your search keyword '"Bosello SL"' showing total 76 results

Search Constraints

Start Over You searched for: Author "Bosello SL" Remove constraint Author: "Bosello SL"
76 results on '"Bosello SL"'

Search Results

1. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement

3. Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy

6. FUNZIONE CARDIORESPIRATORIA, ARTERIAL STIFFNESS E LIVELLI DI NT-PRO BNP IN PAZIENTI AFFETTI DA ARTRITE REUMATOIDE ALL’ESORDIO

7. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study

8. Arthritis in systemic vasculitis: a retrospective analysis

9. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study

10. The human salivary proteome: a critical overview of the results obtained by different proteomic platforms

11. A vascular endothelial growth factor deficiency characterises scleroderma lung disease

12. PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis

13. beta-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up

14. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

15. Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk

16. Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome

17. A vascular endothelial growth factor deficiency characterises scleroderma lung disease

18. Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life.

19. A Comprehensive Natural Language Processing Pipeline for the Chronic Lupus Disease.

20. Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression.

21. Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study.

22. Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry.

23. Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey.

24. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.

25. Extension of Lung Damage at Chest Computed Tomography in Severely Ill COVID-19 Patients Treated with Interleukin-6 Receptor Blockers Correlates with Inflammatory Cytokines Production and Prognosis.

27. Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients.

28. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology.

29. Chronic related group classification system as a new public health tool to predict risk and outcome of COVID-19 in patients with systemic rheumatic diseases: A population-based study of more than forty thousand patients.

30. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study.

31. Lung vascular changes as biomarkers of severity in systemic sclerosis-associated interstitial lung disease.

32. Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic.

33. The role of PET/CT in connective tissue disorders: systemic sclerosis, Sjögren's syndrome and systemic lupus erythematosus.

35. Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: Checklists for Clinical Practice.

38. COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes.

40. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.

41. Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study.

42. What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?

43. Sarilumab use in severe SARS-CoV-2 pneumonia.

44. Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement.

45. No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic.

46. Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis.

47. Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients.

48. Sixth-month remission as a predictor for twelve-month remission in polymyalgia rheumatica.

49. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status.

50. Gender equality in Rheumatology.

Catalog

Books, media, physical & digital resources